Froedtert & the Medical College of Wisconsin said Wednesday it will begin administering remdesivir – an experimental COVID-19 drug that has shown some promise at fighting the coronavirus – to some of its critically ill patients. The health system was recently granted enrollment into California-based biopharmaceutical company Gilead Sciences’ expanded access program to treat COVID-19
To continue reading this article ...
Become a BizTimes Insider today and get immediate access to our subscriber-only content and much more.Learn More and Become an Insider